Today's briefing includes news on health care costs, an update on the shooting of UnitedHealthcare's CEO, election-related ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Eli Lilly and Novo Nordisk continue to ramp production facilities and capacity for booming weight-loss drugs like Wegovy and ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
We recently compiled a list of the 10 Dividend Knights that Beat The Market Last 3 Years. In this article, we are going to ...
A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.